D
espite many advances in therapy, heart failure (HF) continues to exact an enormous human, societal, and economic toll and remains a leading cause of hospitalization, morbidity, and mortality. 1 Among potential new therapies under active investigation are novel stimulators of the cyclic GMP (cGMP)-dependent PKG (protein kinase G)-1α signaling system. [2] [3] [4] [5] This pathway is long known for its vasodilatory role in pulmonary and systemic arterial beds and has historically been leveraged to unload the right and left ventricles (LVs) and reduce pulmonary congestion. PKG1α also confers direct myocardial effects, 6 where it serves as a counterbrake to blunt pathological hypertrophy and fibrotic pathways [7] [8] [9] [10] while also improving calcium homeostasis and reducing myocyte stiffness. 11, 12 Because methods to stimulate PKG1α have expanded, leveraging the therapeutic potential of these myocardial effects has become more feasible.
cGMP is generated by sGC (soluble guanylate cyclase) activated by NO and by particulate GC downstream of natriuretic peptides. Inhibition of selective phosphodiesterases, such as PDE5 (phosphodiesterase type 5), can also elevate cGMP levels 13 to engage PKG1α signaling. Acute studies in humans have used both approaches and reported improvements in rest and exercise physiology in patients with HF, including those with reduced or preserved ejection fraction. 5, 14, 15 Chronic PDE5 inhibition (PDE5-I) has benefited patients with dilated HF in some studies 14 but not those with HF with preserved ejection fraction. 4, 16 A phase II trial with sGC stimulation by vericiguat yielded some promising results with HF and a reduced ejection fraction, but less so in HF with preserved ejection fraction. 2, 3 These findings motivated the current phase III multicenter trial of this compound for HF with reduced ejection fraction (NCT02861534).
A question raised by these variable responses to PDE5 inhibitors versus sGC stimulators is whether these methods of activating PKG1α are interchangeable or whether one method may be particularly more useful in the context of a certain underlying heart disease.
A major factor that impacts both cGMP synthesis and PKG1α signaling is oxidative stress. Oxidation of NO synthase reduces NO generation to favor synthesis of superoxide and contributes to pathological cardiac remodeling, dysfunction, and vascular disease. 17, 18 Oxidation of sGC lessens its NO response to compromise cGMP synthesis. 19 PKG1α can be oxidized at cysteine 42 to form a disulfide bond between homodimer subunits. 20 In resistance arteries, this provides a vasodilatory mechanism in response to H 2 O 2 . 21 However, in myocardium, C42 oxidation reduces the capacity of PKG1α activation to counter hormone, hemodynamic, 22 and cardiotoxic stress. 23 We found this was related to a plasma membrane localization of PKG1α when the kinase is activated in a reduced form as opposed to a diffuse distribution when it becomes oxidized. Such membrane localization favors PKG1α targeting of critical proteins at the plasma membrane that are coupled to HF pathophysiology, enhancing its ameliorative impact. 22 Because the proteins synthesizing or hydrolyzing cGMP are also compartmentalized, 13, 24 redox-controlled relocalization of PKG1α might also alter its activation by different pharmacological methods, producing variable cardiac responses. The present study tests this hypothesis using intact mouse and cellular models and compares the outcome and signaling of a selective PDE5 inhibitor versus sGC activator under each redox state of PKG1α. We reveal that the therapeutic impact of PDE5-I to block pathological stress is greatly hampered in myocytes and intact hearts expressing a redox-dead PKG1α C42S , whereas the efficacy of sGC stimulation is unaltered by the oxidative status of PKG1α.
WHAT IS NEW?
• Cyclic GMP-activated PKG (protein kinase G)-1α conveys signaling linked to the NO and natriuretic peptide pathways. Its activation by PDE5 (phosphodiesterase type 5) inhibition or sGC (soluble guanylate cyclase) activation is being actively tested as a heart failure therapy.
• Oxidation of PKG1α at cysteine 42 reduces its efficacy to counter pathological myocardial stress because of changes in its intracellular localization and thus protein interactions.
• We now show that this oxidation is required to enable PDE5 inhibitors to protect against pathological hormone and mechanical stress, whereas sGC activation is protective, independent of PKG1α redox state.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Post-translational changes in proteins-for example, oxidation or phosphorylation-are well recognized but uncommonly alter the efficacy of pharmaceuticals targeting the protein in an almost binary manner. Oxidative stress is common to most cardiovascular diseases, and PKG1α oxidation is found in failing human hearts. • In the absence of sufficient myocardial stress to stimulate PKG1α oxidation, sGC stimulators may be more effective relative to PDE5 inhibitors.
• When using PDE5 inhibitors in trials or individual patients, the status of myocardial redox maybe an important factor underlying subject response variability.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. This would be accomplished on reasonable and direct request with the corresponding author and data transmitted via a secured server by e-mail.
Experimental Models
The study procedures were approved by the Johns Hopkins Animal Care and Use Committee in accordance with the National Institutes of Health guidelines. PKG1α C42S knock-in (KI) mice were generated on a C57BL6 background as reported previously. 21 Male mutant and littermate controls (WT [wild type]) matched for body size were randomly assigned to experimental groups. Mice were subjected to 3 weeks of pressure overload from transaortic constriction (TAC; 7-0 prolene snare sized to a 27G needle). 18 Surgical controls were subjected to a sham operation. Drug treatments were randomized between a PDE5 inhibitor (sildenafil; 200 mg/kg per day in Bio-Serv soft rodent chow), sGC activator (BAY602770 [BAY]; 0.3 mg/kg per day by oral gavage dissolved in Transcutol:cremophor:water, 1:2:7 volume ratio), or to a corresponding vehicle. BAY602770 is an sGC heme-independent activator similar in action to cinaciguat 25 but different from riociguat or vericiguat that are heme-dependent sGC stimulators. 26 The dose of BAY602770 was selected as the highest that had no impact on arterial blood pressure in chronically treated mice ( Figure  I in the Data Supplement). The sildenafil dose has been shown to be appropriate to achieve therapeutic free plasma concentrations in mice 8 and also has no impact on arterial pressure. Serial echocardiography performed in conscious mice (Acuson Sequoia C256, 13-MHz; Siemens) provided indexes of LV chamber size and function. 18 In our mice, resting LV morphometry and function are nearly identical between both PKG genotypes at the age studied (3-4 months; Figure II in the Data Supplement) and even at 1 year ( Figure III in the Data Supplement). 22 Data analysis was performed blinded to treatment and genotype.
Isolated Myocyte Studies
Neonatal rat ventricular myocytes were freshly isolated and cultured for 24 hours before being infected with recombinant adenovirus encoding human FLAG-tagged PKG1α
WT or PKG1α C42S as described. 22 In other studies, neonatal rat ventricular myocytes were coinfected with adenovirus expressing WT PDE5A, a PKG-phospho-mimetic PDE5 (S92D), or phospho-null PDE5 (S92A). These forms were generated from mouse lung cDNA subcloned into a pDsRed-C1 vector (Clontech). 27 Twenty-four hours after infection, myocytes were stimulated with ET (endothelin)-1 (10 nmol/L) in serumfree DMEM media supplemented with 0.1% insulin-transferrin-selenium (Life Technologies) for 48 hours. Adult myocytes were also studied as described previously, 27 isolated from PKG1α WT or PKG1α C42S hearts and exposed to 8-pCPT-cGMP (100 μM)±sildenafil (1 μM) for 15 minutes with or without the selective PKG1α inhibitor DT3 (1 μM). Myocytes were washed in 1× PBS and flash-frozen as pellets. Lysates were probed by immunoblot for total or phosphorylated PDE5.
Myocardial Analysis
Details of tissue histological and molecular assays for gene and protein expression and phosphorylation are provided in the Data Supplement.
Statistical Analysis
Data in figures are presented as mean±SD unless otherwise noted. The in vivo treatment protocols were performed in separate cohorts, and, therefore, the analysis was performed within each genotype using a mixed factorial ANOVA with cohort and intervention serving as grouping variables, followed by post hoc hypothesis testing between interventions using a Tukey test for multiple comparisons. Additional pairwise testing between gene groups was performed using a Mann-Whitney U test with a multiple comparisons correction (Bonferroni). For isolated tissue and cell culture analysis, 1-or 2-way ANOVA or t tests were used, or if groups failed normality testing or had significantly different variances (Brown-Forsythe test), a nonparametric Kruskal-Wallis or Mann-Whitney U test was used. Sample size and statistical methods and results are provided in each figure and associated legends. Statistical analysis was performed using Systat, version 10, or GraphPad, version 7, software.
RESULTS

PKG1α C42 Oxidation Is Needed for PDE5-I but not sGC Activation to Counter TAC
PKG1α
C42S and littermate PKG1α WT controls were subjected to TAC and treated with the PDE5 inhibitor sildenafil, sGC activator (BAY), or vehicle. In PKG1α Table I in the Data Supplement). Cardiac hypertrophy declined with either sildenafil or BAY treatment (eg, for measured LV mass: −51% and −58% of the increase from TAC alone, respectively; both P<0.0001; P=nonsignificant versus each other). TAC stimulated 45% less hypertrophy in PKG1α C42S mice (P<0.001), as observed previously, 22 although this still was significantly above sham control. In PKG1α C42S mice, however, sildenafil did not reduce heart mass (+5%; P=nonsignificant), whereas it was diminished by BAY (−35%; P<0.03; red symbols, Figure 1A and 1B). The differential effects of the 2 drugs on LV mass between genotypes corresponded with molecular markers of pathological hypertrophy (Nppb and Rcan1), Figure IV in the Data Supplement). We observed similar disparities on indexes of cardiac function ( Figure 1C ) and chamber dilation ( Figure 1D ); sildenafil and BAY improved both in PKG1α
WT after TAC, but only BAY did so in PKG1α C42S . TAC stimulated myocardial fibrosis significantly more in PKG1α
WT than PKG1α C42S hearts, and here too, sildenafil suppressed fibrosis only in PKG1α
WT , where-as BAY did so in both models ( 
Preventing PKG1α C42 Oxidation Blunts PDE5 and Corresponding PKG Activation
A potential mechanism to explain why sildenafil is only effective in TAC hearts expressing WT but not PKG1α C42S relates to the impact of cGMP on the prob- ability of forming the C42 dimer. 23 Binding of cGMP to the regulatory domain of PKG1α leads to physical separation of the N-terminus monomers, reducing the probability of forming a disulfide between C42 residues. 28 As PDE5-I increases cGMP by decreasing its hydrolysis, it could impede PKG1α oxidation and thereby benefit the heart against stress. However, this mechanism would not alter PKG1α C42S hearts because dimerization is already prevented by the mutation. If true, then sildenafil treatment should reduce the PKG1α dimer/monomer ratio in WT after TAC. We examined this and found no change in dimer/monomer ratio from sildenafil in TAC hearts ( Figure 2A) . As shown previously, 22 there was no dimer present in PKG1α
C42S . An alternative explanation for why sildenafil is ineffective in PKG1α C42S mice is that it does not augment PKG1α activity so long as C42 dimerization is prevented. In vitro myocardial PKG1α activity was similarly elevated in both genotypes after TAC ( Figure 2B ). However, whereas TAC+sildenafil increased PKG1α activity further in PKG1α WT , it had no impact in PKG1α C42S mice. By contrast, BAY treatment increased PKG1α activity similarly in both genotypes ( Figure 2B ). We tested whether the disparity in sildenafil activation of PKG1α might be because of less PDE5 expression in PKG1α C42S -TAC hearts. However, although TAC increased PDE5 expression modestly, it did so similarly in both models ( Figure 2C ; Figure VI in the Data Supplement), so this could not explain the disparities. PDE5 activity is also regulated post-translationally, and activity increased after TAC only in PKG1α
WT mice ( Figure 2D ). This lack of PDE5 activation in PKG1α C42S would be anticipated to blunt the impact of PDE5-I therapy.
PKG1α C42-Disulfide Enhances PDE5 Phosphorylation and Thus Activation
To further probe mechanisms underlying the lack of sildenafil responsiveness in PKG1α
C42S
-TAC, we turned to a cell-based model. Neonatal rat ventricular myocytes were infected with adenovirus that expressed WT or C42S mutant PKG1α and then were exposed to 48 hours of ET-1. This hypertrophic stress stimulated Nppb and Rcan1 gene expression (markers of pathological hypertrophy), but induction was less in PKG1α C42S versus PKG1α
WT expressing cells ( Figure 3A and 3B) . Both sildenafil and BAY suppressed gene expression when PKG1α
WT was expressed, but only BAY did so when PKG1α C42S was expressed, recapitulating the in vivo disparities ( Figure 3C ). Similar findings were obtained with phenylephrine as the hypertrophic agonist ( Figure  VII in the Data Supplement). We then tested whether sildenafil or BAY augmented cGMP to the same level independent of the form of PKG1α expressed. Both Figure 3D ).
Myocytes expressing either PKG1α
WT or PKG1α
C42S
were next exposed to the cGMP-analog 8-pCPT-cGMP in combination with hydrogen peroxide (H 2 O 2 , 10 μM, for 20 minutes)-the latter inducing C42 dimerization. 22 We again found PDE5 to be activated only in cells expressing PKG1α WT ( Figure 4A ), despite similar PKG stimulation ( Figure 4B ). Administering cGMP alone without H 2 O 2 resulted in similar increases in PDE5 and PKG activity independent of the form of PKG1α expressed ( Figure VIII in the Data Supplement). Thus, oxidation was required to observe the disparate response because of PKG1α redox genotype.
PDE5 activity is increased by cGMP binding to a regulatory domain in the N-terminus (GAF domains) and by PKG-dependent phosphorylation at serine-92. 29, 30 This provides a negative feedback loop whereby cGMP/ PKG activation results in greater PDE5 activity to counter PKG. Sildenafil stimulated slightly less cGMP in PKG1α
-expressing cells, so this might contribute to reduced PDE5 activity. Serine-92 phosphorylation could also play a role, and this was tested in adult myocytes, where we indeed found sildenafil increased S92 phosphorylation only in cells that expressed PKG1α WT ( Figure 4C ). This change was prevented by coincubation with the PKG inhibitor DT3, supporting involvement of the kinase. To test the functional impact of S92 phosphorylation on hypertrophic modulation by sildenafil, cardiomyocytes expressing either normal PDE5
WT or a mutated phospho-silenced (PDE5
S92A
) or phospho-mimetic (PDE5 S92D ) form were exposed to 48 hours of ET-1 with or without sildenafil. When PDE5 WT or PDE5 S92D was expressed, sildenafil blocked the hypertrophic response. However, this did not happen if PDE-5 S92A was expressed ( Figure 4D ). Thus, the lack of S92 phosphorylation of PDE5 in cells expressing PKG1α
C42S
would be anticipated to lessen PDE5 activity and thus reduce the impact of sildenafil on blunting hypertrophy.
PDE5 Colocalizes With Oxidized PKG1α
WT
More Than With PKG1α
C42S
To determine whether PDE5 and PKG1α interact physically in a manner that hinges on PKG1α oxidation state, we performed immunoprecipitation from neonatal rat ventricular myocytes, pulling down FLAG-tagged PKG1α (WT or C42S) and probing for PDE5. PDE5 coprecipitated with PKG1α, particularly with the addition of H 2 O 2 or cGMP+H 2 O 2 . However, this increase was independent of C42 dimerization (ie, oxidation; Figure 4E and 4F) , so changes in protein-protein interaction were unlikely to explain the results.
An alternative is a change in protein subcellular localization that can be missed in an immunoprecipitation assay. We previously reported that PKG1α C42S translocates to and remains primarily at the outer plasma membrane when cells or hearts are subjected to oxidant, hormone, or hemodynamic stress. 22 By contrast, oxidized WT PKG1α adapts a diffuse cytosolic distribution. Under normal conditions, PDE5 is cytosolic, exhibiting a banding pattern coinciding with the Z-band protein α-actinin, but it becomes more diffuse when cells or hearts are stressed. 31 By contrast, sGC resides both in the cytosol and in the plasma membrane. 24, 32 Using confocal immunohistochemistry, we assessed the intracellular distribution of WT or C42S PKG1α with PDE5 ( Figure 5A ). PDE5 was diffuse and remained so after ET-1 stimulation, and this corresponded to the distribution of PKG1α WT ( Figure 5B ). However, PKG1α C42S was intensified at the outer plasma membrane on exposure to ET-1 and no longer localized with PDE5 ( Figure 5C ). These findings support the notion that the spatial colocalization of PDE5 and PKG1α is diminished in myocytes subjected to stress so long as PKG1α oxidation at C42 is suppressed.
DISCUSSION
In addition to its role in regulating vasomotor tone, cGMP-PKG1α signaling regulates molecular pathways that counter pathological stress. These include its suppression of G q -coupled receptor signaling (eg, angiotensin and ET) by activating regulator of G-protein-coupled signaling RGS (regulator of G-protein signaling) 2 and RGS4, 9, 33 and inhibition of the nonselective cation channel TRPC6 (transient receptor potential canonical channel 6) 34, 35 ; both of which reduce cardiac hypertrophy and fibrosis. Functional cardiac improvement is linked to PKG phosphorylation of phospholamban and troponin I to enhance calcium cycling and relaxation and of titin to increase muscle compliance. 11, 12 PKG1α also provides protection against ischemic injury by improving mitochondrial function, 36 and it enhances protein quality control by increasing activity of the proteasome. 37 The capacity of PKG1α to counter maladaptive stress in cardiomyocytes and the intact heart is further determined by the redox state of an intermolecular disulfide bond formed at Cys42 between its monomers. As reported previously, 22, 23 oxidation of PKG1α at this site diminishes its protective impact, whereas preventing oxidation by expressing a C42S mutation enhances it. We now demonstrate that this post-translational modification is also an important determinant of the therapeutic efficacy of PDE5-I, a common therapy used to stimulate this pathway. Our results are summarized in Figure 6 , which shows that preventing such C42 oxidation decreases stress-induced activation of PDE5 due in part to reduced phosphorylation of PDE5 by PKG at . Pull-down used mouse monoclonal anti-FLAG antibody and gels probed for PDE5A or FLAG to detect dimer/monomer ratio of PKG1α forms. . x axis shows distance (μm) and y axis, fluorescence intensity. In ET-1-exposed cells, PDE5 coincides with PKG1α
WT but not PKG1α C42S outside the nucleus. Neither is nuclear in localization.
serine-92. This means that despite PDE5-I, cGMP-mediated activation of PKG1α is diminished, and the cardioprotective effects that ensue are blunted. This does not apply to activation of sGC, which augments PKG1α activity and suppresses pathological stress regardless of the redox state of PKG1α. These data show relevance of myocardial oxidative stress to the efficacy of pharmacological methods used to stimulate PKG1α, and they likely have implications for precision therapy. PKG1α must interact with specific substrates to achieve its multiple effects, and this is largely regulated by colocalization with the various proteins that generate cGMP or degrade it. An unusual feature of the PKG1α signaling system is that these components are mobile, so interactions and localization can be altered by physiological and pathological signaling inputs. An early example of this mobility was the discovery that inactivation of endothelial nitric oxide synthase (eNOS, also NOS3) in cardiomyocytes leads to migration of PDE5 away from its normal distribution at the z disk to a more diffuse cytosolic distribution. 31, 38 A similar redistribution was demonstrated in chronic heart disease models. 31, 39 Soluble GC shifts from cytosolic to plasma membrane compartments on NO stimulation, and in the heart, the latter is further altered by chronic stress, leading to depressed sGC responsiveness to NO. 24, 32 PKG1α also translocates from the cytosol to the plasma membrane minutes after its stimulation by cGMP, 9 which is reversed on its C42 oxidation. 22 Each of these studies has also shown how a change in location alters the function of a given component of the PKG1α signaling pathway to contribute to myocardial disease. The current investigation supports the conclusion that the effective interaction between PDE5 and PKG1α, but not sGC and PKG1α, is sensitive to the latter's redox state. An alternative explanation might have been that by blocking PKG1α oxidation at C42, the kinase became so effective at countering pathological stress that no further improvement was possible. However, TAC still stimulated pathophysiological changes in PKG1α C42S mice, and importantly, these responses were diminished by sGC activation but not by sildenafil. Another alternative explanation is that sildenafil was not adequately dosed in PKG1α
C42S
-TAC. However, the doses we used were effective in cells and hearts expressing PKG1α WT . Moreover, even if a higher but still selective dose had more impact, this would still mean there is a substantial rightward shift in the dose response to sildenafil in PKG1α
versus WT controls-a finding with therapeutic implications. One prior study proposed that by elevating cGMP, sildenafil prevents C42 dimerization so as to mimic the protective effects from PKG1α C42S 23 . However, we did not find evidence of such changes because the dimer/ monomer ratio in WT-TAC hearts was increased similarly with or without sildenafil treatment. Furthermore, in the current study, we tested an alternative method to stimulate cGMP (sGC activation) and found it was effective, so the prior study's explanation could not apply. Left, By preventing PKG1α oxidation at C42, protection against hormone or hemodynamic stress is enhanced, with less hypertrophy and fibrosis as a result (black arrow). This involves PKG1α C42S translocation to the plasma membrane where it better inhibits RGS (regulator of G-protein signaling) proteins and the cation channel TRPC6 (transient receptor potential canonical channel 6; see text for details). This translocation, however, also moves PKG1α C42S away from PDE5, reducing the impact of PDE5 inhibition (sildenafil [SIL]), whereas sGC activation remains capable of activating PKG1α C42S in this location (blue/purple arrows). Right, PKG1α oxidation blunts its antihypertrophic/antifibrotic effects (black arrow) as it becomes less effective at targeting TRPC6 (as reported previously 22 and depicted by a dashed line). However, the diffuse distribution of oxidized PKG1α means it can be impacted by cyclic GMP (cGMP) enhanced after PDE5 inhibition, so now both BAY and SIL are effective as therapies to enhance antihypertrophic and fibrotic changes (blue/purple arrows). ROS indicates reactive oxygen species.
The PKG1α C42S redox-dead mutant was first shown to suppress resistance artery dilation in response to an oxidant, supporting prior evidence that PKG1α oxidation activates the kinase independent of cGMP. 20 However, Kalyanaraman et al 40 have contested this finding that PKG1α oxidation at C42 directly increases its activity, concluding instead that the C42S mutation reduces its activation by cGMP. In essence, they claim that PKG1α
C42S is a loss-of-function rather than oxidized PKG1α being a gain-of-function mutation. This interpretation, however, cannot explain the behavior in myocardium, where PKG1α C42S is more protective under stress. 22, 23 We agree that PKG1α activity is probably not the primary altered property because of redox change but think its altered localization and consequent interactions are important factors. Kalyanaraman et al 40 did not test this because they used recombinant proteins and in vitro lysates that eliminate subcellular localization effects.
The current findings may have implications for clinical studies involving PDE5 inhibitors. Oxidative stress is a component of most forms of HF, and PKG1α oxidation increases in human failing myocardium. 22 However, the extent of such oxidation likely varies among patients, and this could impact the efficacy of PDE5 inhibitor strategies. In HF with preserved ejection fraction, PDE5-I trials have included many patients with relatively mild cardiac disease and often without ventricular hypertrophy. 4 Yet, prior experimental studies found that the milder the cardiac disease induced by loading stress, the less the therapeutic impact from PDE5-I. 41 The present data provide a new explanation for this finding, as oxidative stress is often greater with more severe disease. Biomarkers of oxidative stress or even oxidation of PKG1α itself may ultimately prove useful to help target PDE5-I therapy. Alternatively, the present findings endorse sGC activation (stimulation) strategies because they are effective regardless of the redox state of PKG1α.
In conclusion, the redox state of PKG1α defined by C42 dimerization determines the therapeutic efficacy of PDE5-I in hearts and cardiomyocytes under pathological stress. By contrast, sGC stimulation is effective regardless of this redox change. The most likely mechanism is that preventing the oxidation of PKG1α depresses its interaction with PDE5, whereas coordinated signaling between proteins is assisted when the kinase is oxidized. This may be specific to PDE5, and further studies assessing other strategies, such as natriuretic peptide stimulation, organic nitrite or nitrate, 42 and PDE9 (phosphodiesterase type-9) inhibitors, 43 are needed. Based on the present results, consideration of oxidative stress and specifically PKG1α oxidation should be made when contemplating the therapeutic use of PDE5 inhibitors.
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